Psyence Biomedical Ltd. (PBM)

Psyence Biomedical Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Selling, General & Admin	2.79	1.8	1.63	2.15
Research & Development	0.43	0.95	1.61	0.17
Operating Expenses	3.22	2.75	3.23	2.32
Operating Income	-3.22	-2.75	-3.23	-2.32
Interest Expense	-0.03	-0.05	-	-
Interest & Investment Income	0	0	0	-
Currency Exchange Gain (Loss)	0.11	-0	0.03	-0
Other Non Operating Income (Expenses)	0.2	-4.69	-	-
EBT Excluding Unusual Items	-2.93	-7.5	-3.21	-2.32
Other Unusual Items	-43.66	-43.66	-	-
Pretax Income	-46.59	-51.16	-3.21	-2.32
Net Income	-46.59	-51.16	-3.21	-2.32
Net Income to Common	-46.59	-51.16	-3.21	-2.32
Shares Outstanding (Basic)	1	0	0	-
Shares Outstanding (Diluted)	1	0	0	-
Shares Change (YoY)	239.30%	30.34%	-	-
EPS (Basic)	-76.91	-588.74	-48.10	-
EPS (Diluted)	-76.91	-588.74	-48.10	-
Free Cash Flow	-2.89	-2.95	-1.59	-1.74
Free Cash Flow Per Share	-4.76	-33.96	-23.88	-
EBITDA	-	-2.75	-	-
D&A For EBITDA	-	0	-	-
EBIT	-3.22	-2.75	-3.23	-2.32

Updated Jan 23, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q